Alemtuzumab in stem cell transplantation

Area of Science:

• Immunology
• Hematology
• Transplantation Medicine

Background:

• Alemtuzumab (CAMPATH-1H) is a monoclonal antibody targeting CD52 on lymphocytes.
• CAMPATH-1 antibodies have a 20-year history in stem cell transplantation for T-cell depletion.
• T-cell depletion aims to prevent graft-versus-host disease (GVHD) and graft rejection.

Purpose of the Study:

• To review clinical trial evolution and protocols for Alemtuzumab in stem cell transplantation.
• To evaluate the benefits and risks of T-cell depletion using Alemtuzumab.
• To assess the impact of different administration protocols and adjunctive therapies on transplant outcomes.

Main Methods:

• Review of clinical trials and evolving protocols for Alemtuzumab use.
• Analysis of T-cell depletion strategies in stem cell transplantation.
• Evaluation of two favored protocols: addition to infusion and in vivo administration.

Main Results:

• T-cell depletion with Alemtuzumab significantly reduces GVHD mortality and morbidity.
• Two protocols (infusion addition, in vivo administration) provide excellent GVHD control with minimal rejection.
• Post-transplant cyclosporin A may reduce transplant-related mortality by decreasing late infectious deaths.

Conclusions:

• Alemtuzumab is a valuable tool for T-cell depletion in stem cell transplantation, balancing GVHD control with risks.
• Current protocols demonstrate efficacy in preventing GVHD and graft rejection.
• Further prospective trials are needed to consolidate findings, particularly regarding the role of cyclosporin A.